Metastatic Breast Cancer | Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics: Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00) Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18) Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harboring ESR1 Mutations — Prof Bidard (35:52) CME information and select publications